Full Text View
Tabular View
No Study Results Posted
Related Studies
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
This study has been completed.
Study NCT00200525   Information provided by Mylan Bertek Pharmaceuticals

First Received on September 13, 2005.   Last Updated on December 15, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson Disease
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Interventions listed in this trial
apomorphine HCl injection
Additional drug interventions recognized in this trial
Apomorphine
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Mylan Bertek Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services